Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
| Condition | Relapsing-remitting Multiple Sclerosis |
|---|---|
| Phase | Phase 1 |
| Sponsor | Cellerys AG |
| Status | Completed |
| Enrollment | 11 participants |
| Interventions | CLS12311 low, CLS12311 medium, CLS12311 high, uncoupled RBCs |
| Start date | Jun 18, 2024 |
| Completion date | Dec 23, 2025 |
| Results posted | Jun 8, 2026 |
Summary
RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS). CLS12311 consists of autologous red blood cells (RBCs) coupled with antigenic peptides and aims to treat RRMS by induction of antigen-specific immune tolerance.
Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety of CLS12311]
| CLS12311 Low | 5 events |
|---|---|
| CLS12311 Medium | 28 events |
| CLS12311 High | 16 events |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of — Mapi Pharma Ltd.
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
- A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
- Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Bioma — Gregory Wu
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche